Protective effects of psoralidin against adriamycin induced myocardial injury

梁振兴,丁宝平,吴振,杨雯雯,陈颖,陈科含,刘海,徐敬,杨阳
DOI: https://doi.org/10.3760/cma.j.cn421213-20210309-01080
2021-01-01
Abstract:Objective:The goal of this study was to explore whether psoralidin (PSO) has a protective effect against myocardial injury induced by adriamycin (ADR).Methods:An appropriate damage HL-1 cell model was established. The experiment was divided into Control group, ADR group (1, 2, 4, 8 μmol/L), and PSO+ ADR group (10, 20, 50, 100 μmol/L) to explore the optimal concentration of ADR and the optimal protective concentration of PSO. The cell viability, reactive oxygen species (ROS) levels and lactate dehydrogenase (LDH) levels in the culture fluid was then detected; The 6-8 week old male BALB/c mice were used for in vivo study. Mice were divided into Sham group, ADR group, PSO+ ADR group. Small animal ultrasound system, automatic blood biochemical analyzer, histopathological staining was used to detect and compare the relevant indicators to clarify the protective effects of PSO against ADR myocardial injury. T-test was used to compare the difference between the two groups, and one-way ANOVA was used to test more than two groups. Results:The cell results showed that compared with the ADR group, 20 μmol/L PSO treatment could significantly increase the viability of myocardial cells ( t=6.694, P<0.05), decrease the level of ROS ( t=10.970, P<0.05) and LDH in the culture medium ( t=4.172, P<0.05). Animal experiment results showed that compared with the ADR group, 25 mg/kg PSO treatment can significantly improve cardiac function, manifested as increased stroke volume (SV) and cardiac output (CO) ( t=4.547, 2.850, P<0.05) and decreased serum creatine kinase (CK) levels ( t=2.545, P<0.05). In addition, the reduced myocardial fibrosis was also observed in PSO-treated mice. Conclusion:PSO conferred a significant cardioprotective effect against ADR injury.
What problem does this paper attempt to address?